Mitral Research Articles

Myxomatous mitral valve disease in Labrador Retrievers and Golden Retrievers.

To characterize myxomatous mitral valve disease (MMVD) in Labrador Retrievers (LRs) and Golden Retrievers (GRs). 52 LRs and 20 GRs diagnosed with MMVD composed a retrospective study sample (February 1, 2010, to July 31, 2021). Stored echocardiograms were remeasured. Dogs were staged by 2019 MMVD consensus guidelines. Mean age was 9.9 years in LRs and 9.5 years in GRs, with 31 of 52 LRs (59.6%) and 13 of 20 (65.0%) GRs being male. Forty-six LRs were stage B1 (88.5%), 3 were B2 (5.8%), and 3 were C (5.8%). Fourteen GRs were stage B1 (70.0%), 2 were B2 (10.0%), and 4 were C (20.0%). Of LRs and GRs in stage B2/C, 50% had systolic dysfunction. Atrial fibrillation (AF) and ventricular arrhythmias were identified in 2 of 52 (3.8%) and 10 of 52 (19.2%) LRs at initial diagnosis versus 3 of 20 (15.0%) and 3 of 20 (15.0%) GRs, respectively. All 5 AF dogs were stage C, with intermediate to high probability of pulmonary hypertension. Two additional GRs developed AF during follow-up; thus 5 of 6 (83.3%) stage B2/C GRs ultimately experienced AF. Subjective mitral valve thickening was frequent in both breeds (41/52 LRs [78.8%]; 18/20 GRs [90.0%]), while mitral valve prolapse was more common in LRs (22/52 [42.3%]) than GRs (5/20 [25.0%]). In LRs and GRs, MMVD was relatively late onset, with males overrepresented. Both breeds exhibited mitral valve thickening in association with MMVD, while LRs more commonly exhibited mitral valve prolapse. While most LRs and GRs with MMVD were stage B1, those in stage B2/C had increased prevalence of systolic dysfunction and AF.

The impact of exercise intensity and duration for swim training-induced adaptations in cardiac structure and function in women with mild hypertension.

This study aimed to investigate the impact of swim training intensity and duration on cardiac structure and function in mildly hypertensive women. Sixty-two mildly hypertensive women were randomized to 15 weeks of either (1) high-intensity swimming (HIS, n = 21), (2) moderate-intensity swimming (MOD, n = 21) or (3) control (CON, n = 20). Training sessions occurred three times per week. Cardiac measurements were conducted using echocardiography pre- and post-intervention. Both the HIS and MOD groups demonstrated significant within-group increases in left ventricular mass: 7.3% [1.2; 13.2] (p = 0.02) for HIS and 6.2% [0.5; 11.8] (p = 0.03) for MOD. The MOD group also demonstrated a significant increase in left ventricular internal dimension at end-diastole by 2.4% [0.2; 4.6] (p = 0.03).Post-hoc analysis of diastolic function markers revealed reduced mitral valve A velocity in both HIS (-14% [-25; -3], p = 0.02) and MOD (-13% [-23; -3], p = 0.01), leading to increased mitral valve E/A ratios of 27% [10; 47] (p = 0.003) and 22% [5; 40] (p = 0.01), respectively. Additionally, only MOD demonstrated increased left atrial diameter of 4.9% [0.7; 9.1] (p =0.02). A significant time×group effect (p = 0.02) existed for global longitudinal strain, which increased by 1.6% [0.2; 3.0] (p = 0.03) in MOD only. In conclusion, swim training for 15 weeks increased left ventricular mass and improved markers of diastolic function in mildly hypertensive women. These independent of exercise intensity and duration in mildly hypertensive women.

Echocardiographic mitral valve segmentation model

Segmentation of mitral valve is not only important for clinical diagnosis, but also has far-reaching impact on prevention and prognosis of the disease by experts and doctors.In this paper, the multi-channel cross fusion transformer based U-Net network model (MCCT-UNet) is proposed according to the classical U-Net architecture. First, the jump connection part of MCCT-UNet is designed by using a multi-channel cross-fusion based attention mechanism module (MCCT) instead of the original jump connection, and this module fuses the feature maps from different scales in different stages of the encoder. Second, the optimization of the feature fusion method is proposed in the decoding stage by designing the cross-compression excitation sub-module (C-SENet) to replace the simple feature splicing, and the C-SENet is used to bridge the inconsistency of the semantic hierarchy by effectively combining the deeper information in the encoding stage with the shallower information. This two modules can establish a close connection between the encoder and decoder by exploring multi-scale global contextual information to solve the semantic divide problem, thus it significantly improves the segmentation performance of the network. The experimental results show that the improvement is effective, and the MCCT-UNet model outperforms the other 9 network models. Specifically, the MCCT-UNet achieved a Dice coefficient of 0.8734, an IoU of 0.7854, and an accuracy of 0.9977, demonstrating significant improvements over the compared models.

Echocardiographic estimates of stroke volume in healthy dogs: Comparability, reference intervals, and reproducibility

Introduction/Objectives: To compare estimates of stroke volume (SV) from different anatomic sites and to generate reference intervals for indices such as shunt volume (ShuntVol) or regurgitant volume (RegVol) in a large sample of healthy dogs. Animals, Materials and MethodsNinety healthy dogs underwent an echocardiogram where SV was assessed at the level of the pulmonary valve (SVPV), aortic valve (SVAV), mitral valve (SVMV), and left ventricle using the difference in end-diastolic volume and end-systolic volume from a right parasternal long-axis four-chamber view (SVLV_RPLx) and left apical four-chamber view (SVLV_Ap4Ch). Eight dogs underwent repeated echocardiograms by the same operator on three different days and by three different operators on the same day. Bland-Altman plots and 95% reference intervals were generated. Reproducibility was described using coefficients of variation (CV) and reproducibility coefficients. ResultsMean difference (95% limits of agreement) for ShuntVol (SVPV-SVAV), RegVolLV_RPLx (SVLV_RPLx-SVAV), RegVolLV_Ap4Ch (SVLV_Ap4Ch-SVAV), and RegVolMV (SVMV-SVAV) were: -0.14 (-0.72, 0.44), -0.05 (-0.59, 0.48), -0.16 (-0.71, 0.39), and 0.12 (-0.76, 1.00) mL/kg, respectively. All but RegVolLV_RPLx showed significant (P<0.01) fixed bias. Reference intervals for ShuntVol, RegVolLV_RPLx, RegVolLV_Ap4Ch, and RegVolMV were: -0.85-0.64, -0.65-0.58, -0.77-0.52, and -0.91-1.06 mL/kg, respectively. Intra-operator and inter-operator CVs were lowest for SVAV, and highest for SVMV and SVLV_AP4Ch, respectively. ConclusionsEchocardiographic estimates of SV are not interchangeable and can exhibit wide limits of agreement. Reference intervals help provide a frame of reference to assess disease severity in dogs with a shunting lesion (ShuntVol) and mitral regurgitation (RegVol).

Assessment of Myocardial Fibrosis in Marfan Syndrome Using Cardiac Magnetic Resonance Imaging.

Impaired myocardial function and arrhythmia are important manifestations of Marfan syndrome (MFS). Studies assessing myocardial fibrosis in relation to these manifestations are scarce. This cross-sectional, single-center study assessed ventricular volumes, ventricular function, and myocardial fibrosis by cardiac magnetic resonance imaging (CMR) in patients with MFS harboring a (likely) pathogenic FBN1 variant. The presence and extent of fibrosis were assessed by late gadolinium enhancement (LGE) and extracellular volume measurement (ECV). Data on 24-h Holter monitoring and clinical data were extracted from electronic patient records. The study included 32 unselected patients with MFS (median age 38 years [range 10-69], 41% women). No focal myocardial fibrosis was detected. Six patients (21%) had diffuse fibrosis (ECV > 29%). No association was found between the presence of diffuse fibrosis and clinically relevant myocardial dysfunction. Five patients (16%) had reduced left ventricular ejection fraction (LVEF < 55%). While all of these exhibited mitral annular disjunction (MAD), only two had ECV > 29%. Patients with MAD had increased indexed LV volumes (median end-diastolic volume, 92 mL/m2 [IQR, 78-100] vs. 78 mL/m2 [IQR, 71-87]; median end-systolic volume, 31 mL/m2 [IQR, 23-46] vs. 22 mL/m2 [IQR, 21-28]), also after adjusting for the presence of mitral and aortic valve regurgitation. No differences in ECV were seen between patients with and without MAD. In this cohort of patients with MFS, focal myocardial fibrosis was not detected using CMR. Although diffuse fibrosis was observed in 21% of patients, no evident connection to clinically relevant myocardial dysfunction was found. Further studies should evaluate the impact of diffuse fibrosis on clinical outcome prediction.

Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement

BackgroundTricuspid regurgitation (TR) and mitral regurgitation (MR) are common valvular conditions encountered in patients undergoing transcatheter aortic valve replacement (TAVR). This retrospective study investigates the impact of moderate or severe TR and MR on all-cause mortality in one-year post-TAVR patients. MethodsConsecutive patients who underwent TAVR at the 3 academic tertiary care centers in our health system between 2012 and 2018 were identified. Patients were stratified into 2 groups based on valvular regurgitation severity: moderate/severe MR vs. no/mild MR, and moderate/severe TR vs. no/mild TR. Primary outcome was all-cause mortality at 1-year and 5-year follow up, and secondary outcome was in-hospital death. Logistic regression analysis was conducted to assess the relationship between moderate/severe MR or TR and all-cause mortality at 1-year and 5-year follow-up. ResultsWe included a total of 1,071 patients who underwent TAVR with mean age 80.9 ± 8.6 years, 97% white, and 58.3% males. Moderate or severe MR group included 52 (4.88%) patients while mild or no MR group included 1,015 (95.12%) patients. There was no significant difference between both groups in TAVR procedure success rate (100% vs. 97.83%, p=0.283), in-hospital mortality (0 vs. 1.08%, p=0.450), or mortality at 1-year follow up (15.38% vs. 14.09%, p=0.794). At 5-year follow up, moderate/severe MR group had higher mortality (61.4% vs. 49.5%, p=0.046). In multivariable logistic regression analysis, moderate or severe MR did not show significant correlation with all-cause mortality at 1-year and 5-year follow up. Moderate or severe TR group included 86 (8.03%) patients while mild or no TR group included 985 (91.97%) patients. There was no difference between both groups in TAVR procedure success (98.8% vs. 97.9%, p=0.54) or in-hospital mortality (0% vs. 1.1%, p=0.33). At 1-year follow up, patients with moderate or severe TR had higher mortality (26.7% vs. 13.2%, p=0.001) compared to patients with mild or no TR. Same finding was noted with extended follow up at 5-years (68.3% vs. 48.7%, p<0.001). In multivariable cox regression analysis, moderate/severe TR was associated with higher all-cause mortality at 1-year (OR 1.94, 95% CI [01.09, 3.44], p=0.0.023) and at 5-year (OR 1.46, 95% CI [1.092, 1.952], p=0.0.011) follow up. Patients with combined moderate/severe MR and TR have even higher mortality compared to either moderate/severe valve regurgitation alone or mild/no valve regurgitation at 5-year follow up. ConclusionAt long term follow up, moderate/severe TR, but not MR, is associated with higher mortality in patients underwent TAVR. Combined moderate/severe TR and MR had even worse mortality. Careful assessment of multi-valvular heart disease prior to the procedure is warranted.

Impact of Right Ventricular Function on Cardiopulmonary Exercise Capacity in Mitral Regurgitation Patients Undergoing Transcatheter Mitral Valve Intervention

Transcatheter mitral valve interventions (TMVI) has been proven to reduce symptom burden and improve outcome in patients with severe mitral regurgitation (MR). However, the impact of right ventricular function (RVF) on exercise capacity in MR patients is less well understood. Cardiopulmonary exercise testing (CPET) is the most comprehensive approach to assess maximum exercise capacity. Submaximal exercise capacity (SEC), assessed by constant work rate exercise time testing (CWRET), is presumed to be relevant in daily life activities, and gives a more differentiated physiological insight into the nature of exercise intolerance. Thus, 28 MR patients underwent CPET and CWRET (at 75% of maximum work rate in the initial incremental exercise test) prior to TMVI and 3-months post-procedurally. Patients´ mean age was 75.0±8.7 years and 32.1% were female. One patient presented with a MR reduction of less than 2 grades. RVF was at least moderately impaired in 25% of the patients. SEC of these patients was lower, but did not significantly differ (416.4s±359.6 vs. 296.1±216.5s; p=) from patients without RVF-deterioration. At follow up, the SEC improved significantly (from 337.4±262.2s to 517.4±393.5s; p=0.006). Maximum oxygen uptake (peakVO2) showed a positive trend, but no statistically significant difference (10.3±3.1ml/min/kg vs. 11.3±3.4ml/min/kg; p=0.06). RVF improved in 35.7% of the patients and these patients showed a significantly higher SEC increase (471.7±153.9s vs. 82.7±47.0s, p=0.003). SEC is significantly increased in MR patients undergoing TMVI, reflecting an improvement especially regarding daily life activities. This may be related to TMVI´s beneficial effect on right ventricular remodeling.

Assessing the use of blood microRNA expression patterns for predictive diagnosis of myxomatous mitral valve disease in dogs

Assessing the use of blood microRNA expression patterns for predictive diagnosis of myxomatous mitral valve disease in dogs

Simplified patch-repair technique for the reinforcement of the posterior mitral valve annulus

Simplified patch-repair technique for the reinforcement of the posterior mitral valve annulus

Breaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review.

Thromboembolic disorders globally contribute to morbidity and mortality, emphasizing adequate anticoagulation and thrombosis management. Therapeutic advances are essential in preventing complications like pulmonary embolism, stroke, and myocardial infarction. This review summarizes recent anticoagulation advances, current challenges, future directions, and novel anticoagulants and drug delivery systems on clinical outcomes. This paper assesses the effectiveness and safety of new anticoagulants through a systematic review of recent clinical trials, meta-analyses, and guideline publications. Key studies, including PACIFIC-AF, RIVER, ENAVLE, ENVISAGE-TAVI AF, and ARCADIA, were analyzed to provide a perspective on therapeutic advancements. The review highlights key findings from vital clinical trials. Asundexian, in the PACIFIC-AF trial, demonstrated a 34% reduction in bleeding events compared to Apixaban. In the RIVER trial, Rivaroxaban reduced significant bleeding events by 20% compared to warfarin in patients with bioprosthetic mitral valves. In the ENAVLE trial, Edoxaban achieved a 3.7% decrease in thromboembolic events compared to warfarin without increasing significant bleeding rates. In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to VKAs in preventing thromboembolic events but showed a slight increase in major bleeding events by 1.5%. Lastly, the ARCADIA trial highlighted that apixaban did not significantly reduce recurrent stroke risk compared to aspirin, with both treatments having an annualized stroke rate of 4.4%. Advances in anticoagulant therapies and drug delivery systems aim to enhance patients' clinical outcomes for thromboembolic disorders. While recent trials show promising data, ongoing patient-specific responses and monitoring challenges require further research. Continuous innovation and investigation are essential to refine anticoagulation practices and tailor treatments.

Comparison of cardiac output index in dogs before and after mitral valve repair as determined using pulse pressure recording analytical methods

Comparison of cardiac output index in dogs before and after mitral valve repair as determined using pulse pressure recording analytical methods

Preoperative left atrial size and functions are predictors of left atrial reverse remodelling after mitral valvuloplasty for myxomatous mitral valve disease in dogs

ObjectivesThe objective of this study was to determine alterations in left atrial size, function, and determinants of left atrial reverse remodelling (LARR) after mitral valvuloplasty (MVP) in dogs with myxomatous mitral valve disease (MMVD). AnimalsThirty-seven dogs undergoing MVP. Materials and MethodsEchocardiographic parameters, including left atrial (LA) strain, were evaluated at baseline, during the early postoperative period (within two weeks), and at one and three months postoperatively. Patients were divided into two groups based on the attainment of LARR, defined as a left atrial to aortic root ratio (LA:Ao) < 1.6 at three months. The predictors of LARR were analysed using univariate logistic regression analysis. ResultsLA:Ao significantly decreased in the early postoperative period (median 1.68; lower and upper quartile 1.54–1.92) compared to baseline (2.41; 2.00–2.80), with a further significant reduction observed at three months (1.46; 1.34–1.63). LARR was achieved in 27 (73%) patients. Baseline LA:Ao was higher, and peak atrial longitudinal strain (PALS) and peak atrial construction strain (PACS) were lower in the non-LARR group than in the LARR group. Among the baseline parameters, PACS was the strongest predictor of LARR (area under the curve, 0.837). ConclusionsFollowing MVP, the LA size decreased in the early postoperative period and continued to decrease over three months of follow-up. A low PACS score was the most reliable predictor of inadequate LARR. Further studies are necessary to determine the relationship between LARR, prognosis, and the optimal timing for surgical intervention.

Minimally Invasive Video-Assisted Surgery for Concomitant Ascending Aorta and Aortic Valve Replacement via Right Infra-Axillary Thoracotomy.

This study aims to assess the safety, efficacy, and esthetic outcomes of an innovative 4 cm right infra-axillary incision approach for concomitant ascending aorta and aortic valve replacement (AAR and AVR), with a specific focus on achieving optimal surgical outcomes while ensuring minimal visible scarring. We retrospectively examined all elective cases of concomitant AAR and AVR surgery performed at our institution from July 2021 to June 2023. Exclusions encompassed emergency surgery, acute type A aortic dissection, active aortic valve endocarditis, redo cardiac surgery, the necessity for concurrent mitral valve replacement, or left ventricular assist device implantation. We collected and analyzed perioperative data for the patients. The study comprised 24 consecutive patients. Cardiopulmonary bypass time and aortic cross-clamp time averaged 215.0 (interquartile range [IQR], 38.0) and 158.0 (IQR, 37.0) min, respectively. No instances of reoperation due to postoperative bleeding or need for permanent pacemaker implantation were recorded. Initial 24-h postoperative drainage volume averaged 186.9 ± 76.9 mL. Average follow-up duration was 21.7 ± 6.2 months (range, 5 to 30 months). Throughout short-term follow-up, no occurrences of valve dysfunction, paravalvular leak, cardiovascular events necessitating readmission, or mortality were observed. The right infra-axillary incision approach effectively yields secure, successful, and cosmetically pleasing outcomes for concomitant AAR and AVR. Further research and comparisons are warranted to validate these findings.

Infrequent Need for Temporary Mechanical Circulatory Support After Mitral Valve Surgery

Infrequent Need for Temporary Mechanical Circulatory Support After Mitral Valve Surgery

Commentator Discussion: Simultaneous sternal-sparing durable left ventricular assist device implantation with aortic and mitral valve procedures

Commentator Discussion: Simultaneous sternal-sparing durable left ventricular assist device implantation with aortic and mitral valve procedures

Clinical Outcomes and Costs of Robotic-assisted versus Conventional Mitral Valve Repair: A National Analysis

Robotic approaches have been increasingly utilized for cardiothoracic operations, though concerns regarding costs remain. We evaluated short-term outcomes and costs of robotic-assisted and conventional mitral valve repair (MV-repair), hypothesizing that cost differences would be mitigated at high-volume programs. Adults undergoing elective MV-repair from 2016 to 2020 were identified in the Nationwide Readmissions Database. Patients with rheumatic heart disease, mitral stenosis, and those undergoing concomitant operations were excluded. Generalized linear models were utilized to evaluate the association between approach and in-hospital mortality, complications, length of stay, costs, and 90-day readmissions. Annual institutional MV-repair volume was modeled using restricted cubic splines, and cost differences subsequently evaluated by volume tertile. Of 40,738 patients, 9.8% underwent robotic-assisted MV-repair. Risk-adjusted outcomes including mortality, stroke, reoperation, respiratory complications, postoperative infection, and readmission were comparable between the two groups, while those undergoing robotic-assisted MV-repair had lower rates of non-home discharge. The median cost of robotic-assisted MV-repair was greater than conventional surgery ($46,800 vs $38,500, p<0.001). Despite a 1.3-day decrement (95% CI 1.1-1.6) in length of stay, robotic-assisted MV-repair was associated with greater risk-adjusted costs by $10,500 (95% CI 5,800-15,200). Programs in the highest volume tertile exhibited comparable costs for robotic-assisted and conventional MV-repair (cost difference $5,900, 95% CI -1,200-12,200, p>0.05). Robotic-assisted MV-repair had comparable short-term outcomes relative to conventional surgery. Despite increased costs of robotic-assisted MV-repair overall, high-volume programs had similar risk-adjusted costs by approach. These findings support the designation and performance of robotic MV-repair at centers of excellence in the United States.

Transesophageal Echocardiography Guidance during Transcatheter Mitral Valve Edge-to-Edge Repair for Severe Mitral Regurgitation Post–Mitral Annuloplasty: A Case Series

Transesophageal Echocardiography Guidance during Transcatheter Mitral Valve Edge-to-Edge Repair for Severe Mitral Regurgitation Post–Mitral Annuloplasty: A Case Series

Infective endocarditis of the mitral valve with involvement of the left atrium: A rare finding

Infective endocarditis of the mitral valve with involvement of the left atrium: A rare finding

Risk of infective endocarditis in patients with mitral valve prolapse: Systematic review with meta-analysis

AimsInfective endocarditis (IE) is a serious heart valvular condition. While mitral valve prolapse (MVP) has been associated with an increased risk of IE, the magnitude of this association remains poorly quantified. This systematic review aimed to better estimate the risk of developing IE among MVP patients compared with the general population. MethodsMEDLINE, Cochrane Library (CENTRAL) and Web of Science databases were searched electronically to find all the relevant cohort and case-control studies. Pooled estimates of odds ratios (ORs) and 95 % confidence intervals (CIs) were derived by random effects meta-analysis. Heterogeneity was assessed using the I2 test. ResultsA total of six studies were considered eligible, and the obtained results showed that MVP patients had a higher risk of IE when compared to the general population (OR 7.83, 95 % CI 5.11, 12.02; I2 = 0 %). Posterior analysis according to the risk of bias and study design didn't show any significant variations in the direction and magnitude of the effect. ConclusionThe magnitude of increased risk of IE of 7-fold warrants further attention for patients with MVP. Further contemporary studies and prophylaxis studies should be considered.

Personalized risk prediction of mortality and rehospitalization for heart failure in patients undergoing mitral valve repair surgery

Personalized risk prediction of mortality and rehospitalization for heart failure in patients undergoing mitral valve repair surgery